Aclaris Therapeutics, Inc. ACRS 深 沪
已收盘 05-08 16:00:00 美东时间
4.93
+0.070
+1.44%
华盛通- 最 高4.94
- 今 开4.83
- 成交量 120.59万股
- 最 低 4.66
- 昨 收 4.86
- 总市值 68.85万
- 52周最高 4.94
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 1.22
- 委 比 -38.49%
- 总股本 0.00亿
- 历史最高 33.88
- 量 比 1.16
- 振 幅 5.76%
- 历史最低 0.5902
- 每 手 1
- 风险率 0.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.12) per share from the same period last year.
05-07 21:23
Aclaris Q1 FY26 net loss widens to $19.8 million; revenue rises to $2 million
Aclaris Q1 FY26 net loss widens to $19.8 million; revenue rises to $2 million Aclaris Therapeutics posted a wider Q1 net loss of $19.8 million, or $0.15 per share, versus a $15.1 million loss a year earlier. Revenue rose 37.18% to $2 million, driven by higher royalties under Lilly and Sun Pharma lic
05-07 18:59
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12
Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $12.
05-05 20:45
美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
Aclaris Reports Positive ATI-052 Phase 1a Trial Results
Aclaris Therapeutics ( ($ACRS) ) has shared an update. On April 28, 2026, Aclar...
04-28 19:19
Aclaris Therapeutics to Reveal Clinical Update On Key Biologic And Oral Inhibitor Programs on April 28, 2026
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results
04-28 04:50
Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains
Veradermics reports Phase 2/3 data for VDPHL01, showing significant hair growth and a safety profile, with shares rising on Monday.
04-27 23:13
Aclaris Therapeutics announces upcoming annual shareholder meeting
Aclaris Therapeutics announces upcoming annual shareholder meeting Aclaris Therapeutics scheduled virtual annual shareholder meeting for June 4, 2026. Ballot includes election of two directors to serve terms ending at 2029 annual meeting. Shareholders will also vote on advisory approval of named exe
04-23 19:48
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
